Overview

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

Status:
NOT_YET_RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

Efficacy and safety of fruquintinib in combination with sintilizumab and SBRT in the treatment of oligonadenocarcinoma progression in the stomach or gastroesophageal junction

Phase:

PHASE2

Details

Lead Sponsor:

Queling Liu

Treatments:

Radiosurgery
sintilimab